{"id":745337,"date":"2016-08-05T07:00:00","date_gmt":"2016-08-05T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/"},"modified":"2025-11-07T01:25:41","modified_gmt":"2025-11-07T06:25:41","slug":"merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/","title":{"rendered":"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine"},"content":{"rendered":"<p class=\"bwalignc\">       Marketing Authorization Application to the European Medicines Agency        Currently Under Review     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside of the United States and Canada,<br \/>\n      today announced that the U.S. Food and Drug Administration (FDA) has<br \/>\n      accepted for review the New Drug Application (NDA) for MK-1293, an<br \/>\n      investigational follow-on biologic<sup>1<\/sup> insulin glargine<br \/>\n      candidate for the treatment of people with type 1 and type 2 diabetes,<br \/>\n      which is being developed by Merck with partial funding from Samsung<br \/>\n      Bioepis.\n    <\/p>\n<p>\n      \u201cThe FDA acceptance of our follow-on biologic application is an<br \/>\n      important milestone, and brings us closer to offering another treatment<br \/>\n      option for people in the U.S. with diabetes,\u201d said Peter Stein, M.D.,<br \/>\n      vice president, late stage development, diabetes and endocrinology,<br \/>\n      Merck. \u201cWe are proud of the significant contributions we have already<br \/>\n      made to helping people with type 2 diabetes, and with investigational<br \/>\n      MK-1293, we hope to expand our portfolio into insulin therapeutics and<br \/>\n      treatments for people with type 1 diabetes.\u201d\n    <\/p>\n<p>\n      The development program for MK-1293 was designed to meet rigorous<br \/>\n      regulatory standards for follow-on biologics of clinical and nonclinical<br \/>\n      safety, efficacy and quality. In addition to Phase 1 studies assessing<br \/>\n      its pharmacokinetic and pharmacodynamic properties, the NDA submission<br \/>\n      for MK-1293 includes <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Fresearch-and-development-news%2Fmercks-investigational-insulin-glargine-mk-1293-met-prima&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=results+of+two+Phase+3+studies&amp;index=1&amp;md5=a406e48e828cf30438ca110b313b8ec3\" rel=\"nofollow\">results<br \/>\n      of two Phase 3 studies<\/a><br \/>\n<span class=\"bwuline\">,<\/span> one conducted<br \/>\n      in people with type 1 diabetes, and one in people with type 2 diabetes;<br \/>\n      Lantus<sup>\u00ae <\/sup>(insulin glargine)<sup>2<\/sup>, the originator<br \/>\n      insulin glargine, was the active comparator in both studies.\n    <\/p>\n<p>\n      The NDA was filed through the 505(b)(2) regulatory pathway<sup>3<\/sup>,<br \/>\n      which allows the FDA to reference previous findings of safety and<br \/>\n      efficacy for an already-approved product (Lantus), in addition to<br \/>\n      reviewing findings from studies of MK-1293. Separately, the Marketing<br \/>\n      Authorization Application for MK-1293, which Merck submitted to the<br \/>\n      European Medicines Agency in December 2015, is currently under review.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=8e79faeb426f5c3e4e5fc8b825548dd2\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=d6dd57f8155f3bfde5a4a420535dee45\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=e259a1f6db0ba1160759376e487e2a26\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=907f6bbcf8bc5c17f0b6131ceeda732f\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=c23287a7ac0d2822a385d56e23cee8ce\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51396386&amp;newsitemid=20160805005285&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=eef95ee5b735a69a52efe20fb7cae371\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> A follow-on biologic is a similar, but not identical,<br \/>\n      version of an approved reference product. In the U.S., MK-1293 is<br \/>\n      referred to as a follow-on biologic because of its regulatory pathway.<br \/>\n      In other countries, MK-1293 is considered to be a biosimilar.\n    <\/p>\n<p>\n      <sup>2<\/sup> LANTUS is a registered trademark of Sanofi-Aventis, which<br \/>\n      is not affiliated with the maker of MK-1293 and does not endorse MK-1293.\n    <\/p>\n<p>\n      <sup>3<\/sup> In the U.S., follow-on insulins, such as MK-1293, are<br \/>\n      reviewed under a different regulatory pathway than biosimilars, which<br \/>\n      follow the 351(k) regulatory pathway.\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20160805005285r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Doris Li, 908-246-5701<br \/>or<br \/>Kristen        Drake, 908-236-4223<br \/>or<br \/>Investors:<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Marketing Authorization Application to the European Medicines Agency Currently Under Review Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis. \u201cThe FDA acceptance of our follow-on biologic application is an important milestone, and brings us closer to offering another treatment option for people in the U.S. with diabetes,\u201d said Peter Stein, M.D., vice president, late stage development, diabetes and endocrinology, Merck. \u201cWe are proud of the significant contributions we have already made to helping people with type 2 diabetes, and with investigational MK-1293, we hope to expand our portfolio into insulin therapeutics and treatments<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745337","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Marketing Authorization Application to the European Medicines Agency Currently Under Review Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis. \u201cThe FDA acceptance of our follow-on biologic application is an important milestone, and brings us closer to offering another treatment option for people in the U.S. with diabetes,\u201d said Peter Stein, M.D., vice president, late stage development, diabetes and endocrinology, Merck. \u201cWe are proud of the significant contributions we have already made to helping people with type 2 diabetes, and with investigational MK-1293, we hope to expand our portfolio into insulin therapeutics and treatments\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\\\/\",\"name\":\"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-08-05T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine - Merck.com","og_description":"Marketing Authorization Application to the European Medicines Agency Currently Under Review Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis. \u201cThe FDA acceptance of our follow-on biologic application is an important milestone, and brings us closer to offering another treatment option for people in the U.S. with diabetes,\u201d said Peter Stein, M.D., vice president, late stage development, diabetes and endocrinology, Merck. \u201cWe are proud of the significant contributions we have already made to helping people with type 2 diabetes, and with investigational MK-1293, we hope to expand our portfolio into insulin therapeutics and treatments","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:41+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/","name":"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-08-05T07:00:00+00:00","dateModified":"2025-11-07T06:25:41+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-u-s-fda-filing-acceptance-of-new-drug-application-nda-for-mk-1293-an-investigational-follow-on-biologic-insulin-glargine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"be119f04-999f-45e0-a02f-daacf4129b0e","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-US-FDA-Filing-Acceptance-of-New-Drug-Application-NDA-for-MK-1293-an-Investigational-Follow-On-Biologic-Insulin-Glargine-2016.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745337\/revisions"}],"predecessor-version":[{"id":3674744,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745337\/revisions\/3674744"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745337"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}